Additional file 1 of Ce6-modified Fe ions-doped carbon dots as multifunctional nanoplatform for ferroptosis and photodynamic synergistic therapy of melanoma
Creators: name: Li, Haiqiu
name: Dou, Yichen
name: Yang, Hang
name: Xing, Hanlin
name: Zhu, Cheng
name: Wang, Tao
name: Xuan, Zhaopeng
name: Yang, Mingxi
Publisher: name: figshare
Year: 2024
Subjects: Medicine
Cell Biology
Pharmacology
Biotechnology
Environmental Sciences not elsewhere classified
Chemical Sciences not elsewhere classified
Developmental Biology
Marine Biology
Cancer
Computational Biology

description: Additional file 1: Figure S1. PL spectra of Fe-CDs under different excitation wavelengths. Figure S2. Deconvoluted C 1s and O 1s XPS spectra of Fe-CDs. Figure S3. FTIR spectrum of Fe-CDs and Fe-CDs@Ce6. Figure S4. XPS full spectra, deconvoluted C 1s and O 1s spectra of Fe-CDs@Ce6. Figure S5. Evaluation of stability of Fe-CDs@Ce6 (2 mg/mL) in PBS (pH=7.4), acidic PBS (pH=5.0) and serum (10% FBS). Figure S6. Photographs of solution for the chromatic reaction of Fe ions and SA. From left to right: SA, SA+FeSO4, SA+Fe-CDs (0.2 mg/mL), SA+Fe-CDs (0.5 mg/mL), SA+GSH-reduced Fe-CDs (0.2 mg/mL), and SA+GSH-reduced Fe-CDs (0.5 mg/mL). Figure. S7 Photographs of solution for the chromogenic reaction of Fe2+ and K3[Fe(CN)6]. From left to right: (a) 0.1 mg/mL K3[Fe(CN)6], (b) 0.1 mg/mL K3[Fe(CN)6] + 0.01 mg/mL FeSO4, (c) 0.1 mg/mL K3[Fe(CN)6] + 0.01 mg/mL Fe2(SO4)3, (d) 0.1 mg/mL K3[Fe(CN)6] + 0.1 mg/mL Fe-CDs, (e) 0.1 mg/mL K3[Fe(CN)6] + 0.2 mg/mL Fe-CDs, (f) 0.1 mg/mL K3[Fe(CN)6] + 0.5 mg/mL Fe-CDs. Figure S8. Evaluation of Fenton reaction by measuring the UV-Vis absorption spectra of MB and H2O2 under different concentrations of Fe-CDs (A) and GSH reduced Fe-CDs (B) (insets show the solution photographs of MB+H2O2 and different concentrations of Fe-CDs and GSH reduced Fe-CDs). Figure. S9 ELISA assay of TNF-α (A) and IL-10 (B) expression level in B16 conditioned medium after Fe-CDs@Ce6+PDT treatment. Figure S10. A-B The levels of ROS in B16 cells after treatment with Fe-CDs (Scale bar: 500 μm). C-D The alteration of mitochondrial membrane potential in B16 cells after treatment with Fe-CDs (Scale bar：100 μm) (n=3, **p&lt;0.01, ***p&lt;0.001 were considered statistically significant). Figure S11. Western blot analysis for β-catenin, xCT, Lef1, HO1 and GPX4 (n=3, *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001 were considered statistically significant). Figure S12. Stimulation of tube formation in HUVECs using B16 cell supernatant after treatment (Scale bar: 200 μm and 100 μm from top to bottom) (n=3, ****p&lt;0.0001 were considered statistically significant). Figure S13. A Macroscopic presentation of tumors, along with measurements of B tumor volume and C mouse body weight (n=6) (Scale bar: 1 cm). Figure. S14 Co-staining of Lyso- and Mito tracker with Fe-CDs@Ce6 at the incubation temperature of 4 and 37°C. Scale bar: 100 μm. Figure. S15 Time-dependent cellular uptake of Fe-CDs@Ce6 by B16 cells at the incubation temperature of 4 and 37°C. Scale bar: 100 μm. Figure S16. The result of H&amp;E staining of main organs of nude mice after treatment (Scale bar: 100 μm). Figure S17. Volcano plot of melanoma in PBS vs Fe-CDs. Figure S18. Immunohistochemical analysis of β-catenin, Lef1, HO1 and GPX4 (n=3, **p&lt;0.01, ***p&lt;0.001, ****p&lt;0.0001 were considered statistically significant). Figure S19. Western blot analysis for β-catenin, xCT, Lef1, HO1 and GPX4 (n=3, **p&lt;0.01, ***p&lt;0.001, ****p&lt;0.0001 were considered statistically significant).